CTOs on the Move

Tizona Therapeutics

www.tizonatx.com

 
Tizona Therapeutics, Inc. is a preclinical stage biotechnology company that is developing multiple, innovative immuno-oncology therapies. Tizona Therapeutics, Inc. was founded by MPM Capital and leading scientists from Dana Farber Cancer Institute, the University of Pittsburgh, Johns Hopkins, Memorial Sloan Kettering Cancer Center, and Brigham and Women`s Hospital.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.tizonatx.com
  • 601 Gateway Blvd Suite 350
    South San Fransico, CA USA 94080
  • Phone: 650.383.0800

Executives

Name Title Contact Details

Funding

Tizona Therapeutics raised $43M on 03/08/2016
Tizona Therapeutics raised $300M on 07/21/2020

Similar Companies

New Hampshire Department of Resources and Economic Development

New Hampshire Department of Resources and Economic Development is a Concord, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

FIRSTMED HOLDING CORP

FIRSTMED HOLDING CORP is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

AiLife Diagnostics

AiLife Diagnostics is a CAP/CLIA laboratory that provides end-to-end genomic testing, interpretation services, and NGS analysis tool.

Vitro Naturals

Vitro Naturals is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Turnstone Biologics

Turnstone Biologics, a privately held clinical stage biotech company, is developing breakthrough cancer immunotherapies by advancing two leading and complementary platforms that drive innate and adaptive tumor immunity, to provide benefit to the millions of cancer patients underserved by current treatment options. Turnstone`s proprietary vaccinia virus platform is engineered to drive coordinated immune activation, potent viral activity, and local expression of encoded therapeutics. The innovative TIL cell therapy platform leverages clinically validated treatment protocols and has been specifically designed to extend beyond the use of bulk TILs to enrich for the most relevant T-cells for tumor eradication, preserving broad antigen diversity and minimizing treatment times to patients. The Company has an ongoing Phase 1/2a trial in solid tumors (RAPTOR) for its leading oncolytic virus candidate, RIVAL-01, and is expecting to file an IND for the lead TIL therapy candidate, TIDAL-01, in 2021.